Taarifa mpya ya 1 kati ya 1Ya hivi karibuniSiku ya 1
NSW records 1,180 peptide-linked emergency visits amid warnings on online products
Fifteen months of NSW surveillance show a sharp rise in emergency presentations associated with peptide use. The warning concerns unapproved products—not every peptide medicine.
TazamaChanzo cha kwanzaABC listen
Tulichojua kwanza
- 1,180Emergency presentations over fifteen months
- 5Presentations in July 2025
- More than 217Presentations in September 2026
- NSW recorded a sharp rise in emergency presentations associated with peptide use, alongside a ministerial warning about serious harm from unregulated products.
Ambacho hakikuwa wazi wakati huo
- The surveillance does not identify the products involved, their verified contents, the number of distinct patients or how many suffered lasting injury.
Tulichosema tungefuatilia
- Product-specific findings, fuller surveillance definitions and patient outcomes would show more clearly what is driving the increase. No date has been announced for the next surveillance release.